Skullcap (Scutellaria lateriflora)

Skullcap (Scutellaria lateriflora) contains baicalin and other flavonoid compounds that interact with GABA receptors to produce calming effects. The herb demonstrates preliminary anti-anxiety and neuroprotective properties through modulation of benzodiazepine binding sites.

Origin & History

Skullcap (Scutellaria lateriflora) is a perennial herb native to North American wetlands and meadows, ranging from Canada to Florida. It is sourced from the aerial parts (leaves, stems, and flowers) of the plant, with extraction typically involving hot water or solvents to yield dried leaf extracts containing approximately 50 mg/g total flavonoids.

Historical & Cultural Context

In North American indigenous and early European settler medicine, particularly the Eclectic tradition, S. lateriflora has been used for centuries as a nerve tonic for anxiety, insomnia, headaches, and convulsions. Historical texts document its application for eye pain, kidney issues, heart conditions, and as a sedative.

Health Benefits

• Anxiety and nervousness support through benzodiazepine receptor binding (preliminary evidence from animal models only)
• Traditional use for insomnia and sleep disturbances (historical/traditional evidence only, no human trials)
• Potential anti-inflammatory effects via flavonoid pathways (preclinical evidence only)
• Possible support for convulsions and nervous system conditions (traditional use only, no clinical trials)
• May help with headaches and tension (traditional use only, lacking human clinical data)

How It Works

Skullcap's primary bioactive compounds baicalin, baicalein, and wogonin bind to benzodiazepine receptor sites, enhancing GABAergic neurotransmission. These flavonoids also inhibit 5-lipoxygenase and cyclooxygenase pathways, reducing inflammatory mediator production. The compounds cross the blood-brain barrier and modulate calcium channels in neural tissue.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Scutellaria lateriflora were identified in the research. Evidence is limited to preclinical studies in animals showing anxiolytic and anticonvulsant activity (PMID 15826062 compares extracts but lacks human trial details), and studies on related species showing immune-modulating effects in mouse models.

Clinical Summary

Clinical evidence for skullcap remains limited, with most research conducted in animal models and cell cultures. One small human study (n=43) showed modest anxiety reduction with 350mg daily over 2 weeks. Animal studies demonstrate significant anxiolytic effects at doses equivalent to 2-6g daily in humans. No large-scale randomized controlled trials have been completed to establish definitive therapeutic efficacy.

Nutritional Profile

Skullcap (Scutellaria lateriflora) is used primarily as a medicinal herb rather than a nutritional food source, so macronutrient content (protein, fat, carbohydrate) is negligible at typical dosing (1–2 g dried herb or 2–4 mL tincture). Its therapeutic value derives from its bioactive compound profile:

**Key Flavonoids (primary active constituents):**
• Baicalin: ~2–6% of dried aerial parts (major glycoside; converted to baicalein by gut microbiota, improving bioavailability)
• Baicalein (aglycone): ~0.5–2% of dried herb; higher bioavailability than baicalin; binds GABA-A receptors at the benzodiazepine site
• Scutellarein: ~0.3–1.5%; methoxylated flavone with anti-inflammatory and neuroprotective activity
• Wogonin: ~0.1–0.8%; anxiolytic flavone that also modulates GABA-A receptors
• Wogonoside (wogonin-7-glucuronide): ~0.2–1.0%
• Lateriflorin: trace amounts; iridoid compound relatively unique to S. lateriflora
• Oroxylin A: trace to ~0.3%; cognitive-enhancing flavone
• Chrysin: trace amounts; weak GABA-A modulator

**Other Bioactive Compounds:**
• Iridoids (catalpol, lateriflorin): trace to low concentrations; contribute to bitter tonic properties
• Phenolic acids (caffeic acid, ferulic acid): ~0.1–0.5%; antioxidant activity
• Volatile oils (limonene, terpineol, others): trace; contribute to aromatic profile
• Tannins: ~2–4% of dried herb; condensed and hydrolyzable types
• Lignins and polysaccharides: present in small amounts

**Minerals (per gram of dried herb, approximate):**
• Calcium: ~5–12 mg/g
• Magnesium: ~2–4 mg/g
• Potassium: ~10–20 mg/g
• Iron: ~0.05–0.2 mg/g
• Zinc: trace
• Manganese: trace

**Vitamins:**
• Minimal vitamin content at typical medicinal doses; trace amounts of vitamin C and B-complex vitamins typical of leafy aerial plant parts

**Fiber:**
• Dried herb contains ~15–25% crude fiber, but given small doses consumed, dietary fiber contribution is negligible

**Bioavailability Notes:**
• Baicalin (glycoside) has relatively low oral bioavailability (~2–5%) due to poor intestinal absorption; however, gut microbiota hydrolyze it to baicalein, which is absorbed more readily (bioavailability ~10–20%)
• Wogonin and baicalein are lipophilic aglycones with moderate oral bioavailability; absorption is enhanced when taken with small amounts of dietary fat
• Tincture (hydroethanolic extract) preparations generally improve extraction and bioavailability of flavonoids compared to simple aqueous infusions
• Glucuronidation in the liver is a major metabolic pathway for all key flavonoids, producing conjugates that undergo enterohepatic recirculation, prolonging activity
• Concurrent intake with grapefruit juice or other CYP3A4 inhibitors may theoretically increase flavonoid plasma levels, though this has not been clinically studied for skullcap specifically

Preparation & Dosage

No clinically studied dosage ranges for S. lateriflora in human trials are available. Traditional preparations involve hot water extracts of dried leaves containing approximately 50 mg/g flavonoids, but standardization protocols are not established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Valerian, Passionflower, Lemon Balm, L-Theanine, Magnesium

Safety & Interactions

Skullcap is generally well-tolerated but may cause drowsiness, especially when combined with sedative medications. It can potentially interact with anticonvulsant drugs, benzodiazepines, and alcohol by enhancing their effects. Pregnancy and breastfeeding safety has not been established through clinical studies. Some commercial skullcap products have been contaminated with hepatotoxic germander species, making source verification critical.